Frequently Asked Questions & Clinical Operations

Operating within clinical laboratory regulatory standards the Silver PGx Oncology Microarray Panel utilizes high-throughput Thermo Fisher genomic processing technology to analyze germline variants influencing systemic chemotherapy metabolism.

Rather than broad, non-specific genetic screening, this targeted panel focuses on high-penetrance alleles with established clinical guidelines. The panel specifically interrogates key pharmacogenes including DPYD (fluoropyrimidines), UGT1A1 (irinotecan), TPMT and NUDT15 (thiopurines), CYP2D6 (tamoxifen), and supporting genes such as CYP2C19, CYP2C9, G6PD, and HLA-B.

The resulting data provides oncologists with immediate, actionable pharmacogenomic guidance to optimize drug selection, manage baseline dosing, and mitigate severe adverse drug reactions (ADRs).

View the current list of genes tested →

The Silver PGx Oncology Panel prioritizes high-penetrance germline genes with established, guideline-backed clinical actionability. The core panel evaluates critical metabolic pathways, explicitly including DPYD (fluoropyrimidine sensitivity), UGT1A1 (irinotecan toxicity risk), and both TPMT and NUDT15 (thiopurine intolerance). These markers map directly to established CPIC and PharmGKB dosing guidelines. To review the comprehensive variant criteria, you can explore our complete Current Genes Tested Page or download our full Clinical Product Insert.

The Silver PGx Oncology Microarray Panel tracks critical metabolic pathways for high-risk chemotherapies and essential supportive care agents—all explicitly mapped to a color-coded, rapid-triage clinical report that eliminates guesswork by clearly highlighting normal genotypes under a "No action currently detected" registry. You can audit our comprehensive, searchable Pharmacogenomics PGx Drug List to see all evaluated molecules, or download our Sample PGx Report to see how these high-penetrance oncology therapeutics are instantly prioritized:

• Irinotecan (UGT1A1): Severe variant status mandates an immediate starting dose reduction to prevent life-threatening neutropenia and toxic diarrhea.

• Tamoxifen (CYP2D6): Intermediate clearance flags lower active concentrations, signaling a need for upper-range dosing or alternative endocrine therapies.

• Supportive Care Pathways: The panel intercepts actionable variants across vital companion therapies, managing risk scaling for post-op analgesics (codeine, tramadol), antiemetics (ondansetron), and chronic GI cardio-support regimens (clopidogrel, omeprazole).

Our clinical informatics engine is continually audited and updated to mirror active medical consensus. The interpretation algorithms utilize real-time data curation to ingest the latest formal updates, dosing modifications, and level-of-evidence shifts published by CPIC, PharmGKB, and the FDA. This rigorous oversight guarantees that your oncology team always receives current, guideline-compliant therapeutic guidance.

The Silver PGx Oncology Panel is a clinical diagnostic assay intended strictly for use by licensed healthcare providers. It is specifically engineered for medical oncologists, hematologic oncologists, and clinical pharmacologists managing patients who may endure multiple systemic therapies. This includes individuals presenting with gastrointestinal, colorectal, breast, or hematologic malignancies where regimens utilize fluoropyrimidines (5-FU, capecitabine), topoisomerase inhibitors (irinotecan), or thiopurines (azathioprine, mercaptopurine).

Licensed healthcare providers can initiate the ordering process by contacting our clinical integration team directly via email at pgxinfo@silvergenelabs.com or by calling 972-807-0649. Our team will immediately provision secure login credentials for your clinic's administrative staff to access our HIPAA-compliant provider portal. Through the portal, clinical teams can securely download digital requisition forms, review specimen collection and shipping logistics, and track real-time sample processing statuses.

Silver Gene Laboratories is an exclusive, clinician-focused pathology framework dedicated entirely to precision oncology diagnostics. Unlike high-volume reference labs that utilize generic, one-size-fits-all panels, our platform specializes in high-density, clinically actionable oncology pathways. Our microarray architecture delivers superior resolution across highly complex genomic loci—including robust copy number variant (CNV) detection for the intricate CYP2D6 gene. By pairing this technical precision with an actionable 6-to-10 day turnaround time and direct, peer-to-peer clinical integration support, we provide oncology practices with an uncompromised standard of germline screening built solely for professional medical environments.

No. To maintain the absolute highest standards of diagnostic accuracy, the Silver PGx Oncology Panel strictly accepts peripheral whole blood specimens. While non-invasive collection methods like buccal swabs or saliva are common in lifestyle testing, they frequently yield low-density or contaminated genomic DNA. Because oncology pharmacogenomics demands zero margin for error before chemotherapy selection, our laboratory mandates whole blood to guarantee pristine sample purity, high-yield allele resolution, and uncompromised technical reliability for every patient report.

The Silver PGx Oncology Panel requires a standard peripheral whole blood specimen. Upon order verification, our laboratory dispatches dedicated specimen collection kits directly to your clinic. Whole blood must be drawn into a lavender-top EDTA tube according to the enclosed instructions. Samples remain stable at room temperature or under standard refrigeration during transport; however, specific ambient shipping guidelines and pre-printed overnight courier labels are included in each kit to preserve specimen integrity during transit.

Active providers can request additional collection supplies by contacting our client services team directly at pgxinfo@silvergenelabs.com or by submitting a rapid supply request through the provider portal. To expedite fulfillment and ensure uninterrupted clinical workflows, please include your clinic name, the primary provider's name, the delivery address, and the specific quantity of kits required. All replenishment orders are processed immediately and dispatched via standard courier.

The standard turnaround time is 7 to 10 calendar days, initiated immediately upon sample accessioning at our laboratory facility. To prevent delays in clinical treatment cycles, finalized diagnostic reports are delivered securely through our HIPAA-compliant provider portal the moment analysis is complete. Real-time automated email notifications ensure the ordering oncology team has immediate access to the actionable dosing guidance required before therapy initiation.

Our clinical reports are engineered specifically for rapid interpretation within high-volume oncology workflows. Each report features a color-coded risk stratification summary detailing the patient's specific metabolizer phenotypes (e.g., poor, intermediate, or ultra-rapid metabolizer statuses). This is paired with explicit, drug-by-drug actionable guidance directly sourced from current CPIC and NCCN consensus recommendations. To evaluate our clear formatting, intuitive evidence mapping, and clinical integration notes. 

Silver Gene Laboratories is a high-complexity molecular laboratory actively pursuing both CLIA certification and CAP accreditation.

We are currently in the final stages of the CLIA certification process with the Centers for Medicare & Medicaid Services (CMS) and simultaneously preparing for College of American Pathologists (CAP) accreditation.

These are the key regulatory benchmarks for clinical laboratories performing human specimen testing.

Our laboratory follows stringent internal quality systems, validated testing protocols, and best practices in pharmacogenomics to ensure accuracy and reliability as we complete these formal accreditations. We expect to announce full CLIA certification and progress on CAP accreditation very soon.

We offer flexible financial frameworks tailored to the specific procurement requirements of individual practices, multi-site oncology groups, and hospital networks. Because overall pricing depends on volume agreements and your preferred billing model (such as direct institutional billing or automated third-party insurance processing), customized pricing schedules are detailed within our formal corporate onboarding packages. Our dedicated client services team handles all structural billing inquiries, provides clear out-of-pocket estimations, and assists with insurance documentation to guarantee complete financial transparency before sample collection.